Advertisement

The American College of Physicians guidelines for screening blood cholesterol levels: a commentary

  • Michael H. Criqui
    Correspondence
    Requests for reprints should be addressed to Michael H. Criqui, MD, MPH, University of California, San Diego, Department of Family and Preventive Medicine, 9500 Gilman Drive, La Jolla, California 92093-0607
    Affiliations
    University of California, San Diego, Department of Family and Preventive Medicine and Department of Medicine, San Diego, California, USA (M.H.C.)
    Search for articles by this author
  • Bruce Kinosian
    Affiliations
    Division of General Internal Medicine, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA (H.G., B.K.)
    Search for articles by this author
  • Henry Glick
    Affiliations
    Division of General Internal Medicine, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA (H.G., B.K.)
    Search for articles by this author
  • Prakash C. Deedwania
    Affiliations
    Cardiology Division, Department of Medicine, University of California, San Francisco School of Medicine, San Francisco, California, USA

    Stanford University Medical Center, Palo Alto, California, USA (P.C.D.)
    Search for articles by this author
  • Ronald M. Krauss
    Affiliations
    Donner Laboratory, Lawrence Berkeley National Laboratory, University of California, Berkeley, Department of Molecular and Nuclear Medicine, Berkeley, California, USA (R.M.K.)
    Search for articles by this author
      Recently, the American College of Physicians (ACP) issued revised guidelines on the use of serum cholesterol, high-density lipoprotein (HDL) cholesterol, and triglyceride levels as screening tests for preventing coronary artery disease in adults.
      American College of Physicians
      Guidelines for using serum cholesterol, high-density lipoprotein cholesterol, and triglyceride levels as screening tests for preventing coronary heart disease in adults.
      Of these tests, only blood cholesterol level was recommended for use in screening, and screening was felt to be appropriate only for men 35–65 years of age and women 45–65 years of age. Both of these positions are departures from the prior guidelines from the ACP and also differ markedly from the National Cholesterol Education Program’s (NCEP) guidelines.
      The Expert Panel
      Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • American College of Physicians
        Guidelines for using serum cholesterol, high-density lipoprotein cholesterol, and triglyceride levels as screening tests for preventing coronary heart disease in adults.
        Ann Intern Med. 1996; 124: 515-517
        • The Expert Panel
        Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults.
        JAMA. 1993; 269: 3015-3023
        • Garber A.M.
        • Browner W.S.
        • Hulley S.B.
        Cholesterol screening in asymptomatic adults, revisited.
        Ann Intern Med. 1996; 124: 518-531
        • Tribble D.L.
        • Krauss R.M.
        HDL and coronary artery disease.
        Adv Intern Med. 1993; 38: 1-29
        • Kinosian B.
        • Glick H.
        • Garland G.
        Cholesterol and coronary heart disease.
        Ann Intern Med. 1994; 121: 641-647
        • Kinosian B.
        • Glick H.
        • Preiss L.
        • Puder K.L.
        Cholesterol and coronary heart disease.
        J Investig Med. 1995; 43: 443-450
        • Criqui M.H.
        • Heiss G.
        • Cohn R.
        • et al.
        Plasma triglyceride level and mortality from coronary heart disease.
        N Engl J Med. 1993; 328: 1220-1225
        • Laakso M.
        • Lehto S.
        • Penttilä I.
        • Pyörälä K.
        Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes.
        Circulation. 1993; 88: 1421-1430
        • Carlson L.A.
        • Rosenhamer G.
        Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid.
        Acta Med Scand. 1988; 223: 405-418
        • Miller B.D.
        • Krauss R.M.
        • Cashin-Hemphill L.
        • et al.
        Baseline triglyceride levels predict angiographic benefit of colestipol plus niacin therapy in the Cholesterol-Lowering Atherosclerosis Study (CLAS).
        Circulation. 1993; 88 (Abstr.): I-363
        • Austin M.A.
        • Hokanson J.E.
        • Edwards K.L.
        Hypertriglyceridemia as a cardiovascular risk factor.
        Am J Cardiol. 1998; 81: 7B-12B
        • Krauss R.M.
        Triglycerides and atherogenic lipoproteins.
        Am J Med. 1998; 105: 58S-62S
        • Frost P.H.
        • Havel R.J.
        Rationale for use of non-high-density lipoprotein cholesterol rather than low-density lipoprotein cholesterol as a tool for lipoprotein cholesterol screening and assessment of risk and therapy.
        Am J Cardiol. 1998; 81: 26B-31B
        • Scandinavian Simvastatin Survival Study Group
        Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease.
        Lancet. 1994; 344: 1383-1389
        • Sacks F.M.
        • Pfeffer M.A.
        • Moye L.A.
        • et al.
        The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels.
        N Engl J Med. 1996; 335: 1001-1009
        • Corti M.C.
        • Gurainik J.M.
        • Salive M.E.
        • et al.
        HDL cholesterol predicts coronary heart disease mortality in older persons.
        JAMA. 1995; 274: 539-544
        • Corti M.C.
        • Guralnik J.M.
        • Salive M.E.
        • et al.
        Clarifying the direct relation between total cholesterol levels and death from coronary heart disease in older persons.
        Ann Intern Med. 1997; 126: 753-760
        • Kuller L.H.
        • Shemanski L.
        • Psaty B.M.
        • et al.
        Subclinical disease as an independent risk factor for cardiovascular disease.
        Circulation. 1995; 92: 720-726
        • Fleg J.
        • Gerstenblith G.
        • Zonderman A.B.
        • et al.
        Prevalence and prognostic significance of exercise-induced silent myocardial ischemia detected by thallium scintigraphy and electrocardiography in asymptomatic volunteers.
        Circulation. 1990; 81: 428-436